Skip to main content
OpenTrials
Recruiting

NCT Number: NCT00349830

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Carcinomas (Including Squamous Cell and Adenocarcinoma) Adenocarcinoma Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

Location status: Recruiting

Location contact

Maximilian Diehn

PRINCIPAL_INVESTIGATOR

Rene Bonilla

CONTACT

[email protected]

650-498-7703

About this study

This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

  • Age > or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled.
  • Prior diagnosis of cancer or suspected of having cancer
  • Karnofsky performance status of greater than 70
  • Standard pretreatment evaluation
  • Signed Stanford University Human Subjects Committee consent

Treatment and study plan

Blood draw

Procedure

Primary outcomes

  1. Biomarkers for disease

    Time frame: Day one

Study contacts

Contact information is provided by the study sponsor or research team.

[email protected]

CONTACT

[email protected]

650-498-7757

[email protected] [email protected]

CONTACT

[email protected]

650-498-7757

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Important dates

Study start
2002
Primary completion
2032
Study completion
2032
First posted
Jul 10, 2006
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.